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Neurobiology of Disease
NF-B Activation Protects Oligodendrocytes against
Inflammation
Sarrabeth Stone,1,2 Stephanie Jamison,1,2 Yuan Yue,1,2Wilaiwan Durose,1,2 XRuth Schmidt-Ullrich,3
and XWensheng Lin1,2
1Department of Neuroscience and 2Institute for Translational Neuroscience, University of Minnesota, Minneapolis, Minnesota 55455, and 3Department of
Signal Transduction in Tumor Cells, Max-Delbru¨ck-Center for Molecular Medicine, Berlin-Buch 13125, Germany
NF-B is a key player in inflammatory diseases, including multiple sclerosis (MS) and its animal model, experimental autoimmune
encephalomyelitis (EAE). However, the effects of NF-B activation on oligodendrocytes inMS and EAE remain unknown.We generated
a mouse model that expresses IBN, a super-suppressor of NF-B, specifically in oligodendrocytes and demonstrated that IBN
expression had no effect on oligodendrocytes under normal conditions (both sexes). Interestingly, we showed that oligodendrocyte-
specific expression of IBN blocked NF-B activation in oligodendrocytes and resulted in exacerbated oligodendrocyte death and
hypomyelination in young, developing mice that express IFN- ectopically in the CNS (both sexes). We also showed that NF-B inacti-
vation in oligodendrocytes aggravated IFN--induced remyelinating oligodendrocyte death and remyelination failure in the cuprizone
model (malemice). Moreover, we found that NF-B inactivation in oligodendrocytes increased the susceptibility ofmice to EAE (female
mice). These findings imply the cytoprotective effects of NF-B activation on oligodendrocytes in MS and EAE.
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Introduction
Multiple sclerosis (MS) and its animal model, experimental
autoimmune encephalomyelitis (EAE), are inflammatory demy-
elinating diseases of the CNS characterized by inflammation,
demyelination, oligodendrocyte death, and axon degeneration
(Frohman et al., 2006; Bradl and Lassmann, 2010). It is believed
that mature oligodendrocyte death induced by inflammation
contributes significantly to the pathogenesis of MS and EAE. A
number of studies have shown that protection of mature oligo-
dendrocytes against inflammation decreases the susceptibility of
mice to EAE (Hisahara et al., 2003; Mc Guire et al., 2010; Prineas
and Parratt, 2012; Lin et al., 2013). Oligodendrocyte regeneration
is necessary to repair myelin damage in MS lesions; however,
remyelinating oligodendrocytes are prone to apoptosis under in-
flammatory conditions (Franklin and ffrench-Constant, 2008;
Watzlawik et al., 2010; Stone and Lin, 2015). One of the major
challenges in MS research is to understand the mechanisms gov-
erning the viability of oligodendrocytes and to develop therapeu-
tic strategies that promote oligodendrocyte survival.
The transcription factor NF-B is a heterodimer or ho-
modimer of the Rel family of proteins, including p65, c-Rel, RelB,
p50, and p52. In the quiescent state, NF-B remains inactive in
the cytoplasm through interaction with NF-B inhibitors (IBs).
Activation of NF-B involves dissociation from IBs and trans-
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Significance Statement
Multiple sclerosis (MS) is an inflammatory demyelinating disease of the CNS. NF-B is a major player in inflammatory diseases
that acts by regulating inflammation and cell viability. Data indicate that NF-B activation in inflammatory cells facilitates the
development of MS. However, to date, attempts to understand the role of NF-B activation in oligodendrocytes in MS have been
unsuccessful. Herein, we generated amousemodel that allows for inactivation of NF-B specifically in oligodendrocytes and then
used this model to determine the precise role of NF-B activation in oligodendrocytes in models of MS. The results presented in
this study represent the first demonstration that NF-B activation acts cell autonomously to protect oligodendrocytes against
inflammation in animal models of MS.
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location into the nucleus, where NF-B binds to the B consen-
sus DNA sequence and stimulates transcription of genes that
regulate inflammation, cell viability, and cell functions. NF-B
can be activated in a variety of ways, including the IB kinase 2
(IKK2)-dependent canonical pathway, the noncanonical pathway,
and atypical pathways (Hayden and Ghosh, 2012; Mincheva-
Tasheva and Soler, 2013). It is known thatNF-Bplays a critical role
inMS andEAE (Yan andGreer, 2008;McGuire et al., 2013).NF-B
is activated in multiple cell types in MS and EAE, including oligo-
dendrocytes, T cells, astrocytes, andmicroglia/macrophages (Gveric
et al., 1998; Bonetti et al., 1999; Lin et al., 2013). A number of studies
have shown that NF-B activation in T cells, microglia/macro-
phages, or astrocytes promotes the development ofMS and EAE by
facilitating inflammation (Brambilla et al., 2009; Mc Guire et al.,
2013; Yin et al., 2013; Hao et al., 2016).
In vitro studies suggest that NF-B activation promotes oligo-
dendrocyte survival in response to inflammatory mediators
(Nicholas et al., 2001; Hamanoue et al., 2004; Lin et al., 2012). In
contrast, one study briefly mentions that IKK2 deletion in oligo-
dendrocytes using the Cre/loxP approach by crossing floxed
IKK2 mice (IKK2FL mice) with mice expressing Cre under the
myelin oligodendrocyte glycoprotein (MOG) promoter (MOG/
Cre mice) does not alter the EAE disease course (Raasch et al.,
2011). However, the study falls short of excluding the following
possibilities: (1) that NF-B activation is not attenuated in
oligodendrocytes of IKK2FL;MOG/Cre mice during EAE due to
insufficient efficiency of Cre-mediated recombination and/or
compensation from other NF-B activating pathways and (2)
that inflammation is compromised in IKK2FL;MOG/Cre mice
undergoing EAE due to undesired leaky expression of Cre in
inflammatory cells. Theminimal alteration of EAE disease course
in IKK2FL;MOG/Cre mice does not rule out the significant im-
pact of NF-B activation on oligodendrocytes during EAE.
Therefore, the effects of NF-B activation on oligodendrocytes in
MS and EAE remain ambiguous.
Our previous studies demonstrated that NF-B is activated in
oligodendrocytes in the CNS of mice undergoing EAE and mice
that express IFN-, a key proinflammatory cytokine in MS and
EAE, ectopically in the CNS (Lin et al., 2012, 2013). Importantly,
our previous in vitro study showed that expression of IBN, a
super-suppressor of NF-B, is sufficient to block NF-B activa-
tion in the oligodendroglial cell lineOli-neu in response to IFN-
and render the cells sensitive to this cytokine (Lin et al., 2012).
Therefore, in this study, we sought to determine the role of
NF-B activation in oligodendrocytes in models of MS by ex-
ploiting a mouse model that expresses IBN specifically in
oligodendrocytes.Our findings indicate the cytoprotective effects
of NF-B activation on oligodendrocytes in MS and EAE.
Materials andMethods
Mice, cuprizone treatment, and EAE immunization. A summary of mouse
lines can be found in Table 1 and a summary of experimental genotypes
and crosses can be found in Table 2. cloxPIBNmice, CNP/Cremice,
GFAP/tTA mice, and TRE/IFN- mice were on the C57BL/6J back-
ground. cloxPIBN mice were crossed with CNP/Cre mice to obtain
cloxPIBN;CNP/Cremice and control mice, including cloxPIBN
mice, CNP/Cremice, and wild-type mice. GFAP/tTAmice were crossed
with CNP/Cremice to obtain GFAP/tTA;CNP/Cremice and TRE/IFN-
mice were crossed with cloxPIBN mice to obtain TRE/IFN-;
cloxPIBN mice. Then, GFAP/tTA;CNP/Cre mice were crossed
with TRE/IFN-;cloxPIBN mice to obtain GFAP/tTA;TRE/IFN-;
cloxPIBN;CNP/Cre quadruple mice and GFAP/tTA;TRE/IFN-
double mice. Genotypes were determined by PCR from DNA extracted
from tail tips as described previously (Schmidt-Ullrich et al., 2001;
Lappe-Siefke et al., 2003; Lin et al., 2004). To repress the expression
of the IFN- transgene in the astrocytes of GFAP/tTA;TRE/IFN-;
cloxPIBN;CNP/Cremice andGFAP/tTA;TRE/IFN-mice, 0.05 mg/ml
doxycycline (Dox)was added to the drinkingwater and provided ad libitum
from conception (Lin et al., 2004, 2005, 2006).
To induce demyelination with cuprizone, 6-week-old male mice were
fed a diet ofmouse chow containing 0.2% cuprizone (Sigma-Aldrich) for
up to 6 weeks. Subsequently, mice were returned to a normal diet for 3
weeks to allow remyelination to occur (Lin et al., 2006, 2014). To induce
EAE, 8-week-old female mice were injected subcutaneously in the flank
and at the tail base with 200 g of MOG 35–55 peptide emulsified in
complete Freund’s adjuvant (BDBiosciences) supplementedwith 600g
of Mycobacterium tuberculosis (strain H37Ra; BD Biosciences). Two in-
traperitoneal injections of 400 ng of pertussis toxin (List Biological
Laboratories) were given 24 and 72 h later. Clinical scores (0 healthy,
1 flaccid tail, 2 ataxia and/or paresis of hindlimbs, 3 paralysis of
hindlimbs and/or paresis of forelimbs, 4 tetraparalysis, 5moribund
or death) were recorded daily (Lin et al., 2007, 2013, 2014).
All animal procedures were conducted in complete compliance with
the National Institutes of Health’s Guide for the Care and Use of Labora-
tory Animals and were approved by the Institutional Animal Care and
Use Committee of the University of Minnesota.
PCR and real-time PCR.Deeply anesthetized mice were perfused with
ice-cold PBS. Genomic DNA was isolated from the indicated tissues and
PCR was performed to determine the removal of the floxed STOP
cassette that prevents IBN translation by Cre recombination in
cloxPIBN;CNP/Cre mice as described previously (Schmidt-Ullrich
et al., 2001). RNA was isolated from brain using TRIzol reagent (Invit-
rogen) and treatedwithDNaseI (Invitrogen) to eliminate genomicDNA.
Reverse transcription was performed using the iScript cDNA Synthesis
Kit (Bio-Rad). TaqMan real-time PCRwas performed with iQ Supermix
(Bio-Rad) on the LightCycler 480 System (Roche) as described in our
previous studies (Lin et al., 2006, 2007; Lin and Lin, 2010).
Western blot analysis. Brains harvested from mice were rinsed in ice-
cold PBS and homogenized using amotorized homogenizer as described
previously (Lin et al., 2005, 2008). After incubating on ice for 15min, the
extracts were cleared by centrifugation twice at 14,000 rpm for 30 min.
The protein content of each extract was determined by DC Protein Assay
(Bio-Rad Laboratories). The extracts (40 g) were separated by SDS-
PAGE and transferred to nitrocellulose membranes. The membranes
were incubated with a primary antibody against IB (1:1000; Santa
Cruz Biotechnology, RRID:AB_2235952) or -actin (1:5000; Sigma-
Aldrich, RRID:AB_476694), followed by an HRP-conjugated secondary
antibody (1:1000; Vector Laboratories, RRID:AB_2336198). After incu-
bation with ECL Detection Reagents (GE Healthcare Biosciences), the
chemiluminescent signal was detected.
Immunohistochemistry (IHC). Anesthetized mice were perfused
through the left cardiac ventricle with 4% paraformaldehyde in PBS. The
tissues were removed, postfixed with paraformaldehyde, cryopreserved
in 30% sucrose, embedded in optimal cutting temperature compound,
and frozen on dry ice. Frozen sections were cut using a cryostat at a
thickness of 10 m. For immunohistochemistry, the sections were
treated with 20°C acetone, blocked with PBS containing 10% goat
serum and 0.1% Triton X-100, and incubated overnight with the
primary antibody diluted in blocking solution. Fluorescein (Vector
Laboratories, anti-rabbit, RRID:AB_2336197), Cy3 (Millipore, anti-
mouse, RRID:AB_11213281, anti-rat, RRID:AB_90854), or enzyme-
labeled secondary antibodies (Vector Laboratories, anti-rat, RRID:
Table 1. Summary of mouse lines
Mouse line Description Citation
cloxPIBN Carry a floxed conditional allele of IBN Schmidt-Ullrich et al., 2001
CNP/Cre Express the Cre recombinase under the control
of the CNP promoter
Lappe-Siefke et al., 2003
GFAP/tTA Express the tTA under the control of the GFAP
promote
Lin et al., 2004
TRE/IFN- Express IFN- under the control of the TRE Lin et al., 2004
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AB_2336202; anti-mouse, RRID:AB_2313581) were used for detection.
Immunohistochemical detection of CC1 (APC7, 1:50; EMDBiosciences,
RRID:AB_2057371), myelin basic protein (MBP,1:1000; Sternberger
Monoclonals, RRID:AB_10120129), CD3 (1:50; Santa Cruz Biotechnol-
ogy, RRID:AB_627010), CD11b (1:50; Millipore, RRID:AB_92930), the
active form of p65 (1:50; Millipore, RRID:AB_2178887), glial fibrillary
acidic protein (GFAP; 1:200; Agilent Technologies, RRID:AB_10013382),
and aspartoacylase (ASPA, 1:1000, kindly provided by Dr. M.A. Aryan
Namboodiri at Uniformed Services University of the Health Sciences,
Bethesda, MD; Madhavarao et al., 2004) were performed. Fluorescent
stained sections were mounted with Vectashield mounting medium with
DAPI (Vector Laboratories) and visualized with an Olympus FV1000 con-
focal microscope.
For cuprizone-treated mice, coronal sections of the fornix region of
the corpus callosum corresponding to Sidman sections 241–251 were
selected for use and all comparative analyses were restricted to the mid-
line corpus callosum (Sidman et al., 1971). Immunopositive cells were
quantified by counting positive cells within the median of the corpus
callosum as described previously (Lin et al., 2006, 2014).
Toluidine blue staining and electron microscopy (EM) analysis. Mice
were anesthetized and perfused with PBS containing 4% paraformalde-
hyde and 2.5% glutaraldehyde. The sciatic nerve, spinal cord, cerebellar
white matter, and corpus callosum were processed and embedded. For
cuprizone-treated mice, brains were sliced into 1 mm sections. The sec-
tion corresponding to the region of the fornix was trimmed, processed,
and oriented so that a cross-section of the corpus callosumwas achieved.
Thin sections were cut, stained with toluidine blue, and analyzed as de-
scribed previously (Lin et al., 2013, 2014). Moreover, ultrathin sections
were cut, stained with uranyl acetate and lead citrate, and analyzed as
described previously (Lin et al., 2013, 2014). We counted the total num-
ber of axons, the number of myelinated axons, and calculated the per-
centage of myelinated axons as described previously (Lin and Lin, 2010;
Lin et al., 2014).
T-cell proliferation assay and cytokine assay. Single-spleen cell suspen-
sions were generated from mice with EAE at postimmunization day
(PID) 10. Red blood cells were lysed with ACK lysis buffer (Invitrogen),
washed, and plated at 5 105 splenocytes per well in 96-well microtiter
plates. Samples were plated in triplicate. The cells were treated with
MOG35-55 peptide (0, 1, 10, or 100 g/ml) and incubated at 37°C and
5% CO2. After 48 h, 20 l of BrdU labeling solution (Millipore) was
added to the culture medium for 24 h. Cell proliferation was determined
using the Colorimetric BrdU Cell Proliferation kit (Millipore) according
to manufacturer’s instructions. We quantified the cytokines in the cul-
ture supernatants of triplicate wells using the ELISA kits (Thermo Scien-
tific) according to the manufacturer’s instructions.
Experimental design and statistical analysis. The sample size for each
individual experiment is listed in the corresponding figure legend. For
EAE experiments, only female mice were used due to the well known sex
differences in EAE. For cuprizone studies, only male mice were used. For
developmental studies, bothmale and female mice were used because no
sex differences were observed. EAE clinical score data are presented as
mean  SEM and were compared using a two-way ANOVA with a Si-
dak’s multiple-comparisons test using GraphPad Prism 6 software
(RRID:SCR_002798). All other data are expressed as mean SD. Com-
parisons between two groups was evaluated by t test using GraphPad
Prism 6 software. Multiple comparisons were evaluated statistically with
one-way ANOVA with Tukey’s posttest using GraphPad Prism 6 soft-
ware. Phenotypic differences among groups were evaluated with the  2
test using GraphPad Prism 6 software. p  0.05 was considered
significant.
Results
NF-B is dispensable for oligodendrocytes under
normal conditions
The primary function of oligodendrocytes is to produce the my-
elin that insulates axons in theCNS.Data indicate thatNF-Bhas
no significant effect onmyelin formation andmaintenance in the
CNS under normal conditions (Blank and Prinz, 2014; Kretz et
al., 2014). Mice with deletions in the genes encoding c-Rel, RelB,
or p52 do not exhibit myelin abnormalities in the CNS (Hilliard
et al., 1999, 2002). Similarly,micewithCNS-restricted deletion of
p65, IKK1, IKK2, or IKK3 do not show any myelin defects in the
CNS (van Loo et al., 2006; Kretz et al., 2014). Nevertheless, a
recent study shows that impaired NF-B activity is associated
with myelin abnormalities in the CNS of patients with Xq28 du-
plication (Philippe et al., 2013). We generated a mouse model
that expresses IBN, a deletionmutant lacking theN-terminal
36 aa of IB that functions as a dominant inhibitor of NF-B
signaling (Krappmann et al., 1996), specifically in oligodendro-
cytes in the CNS and determined the potential role of NF-B in
these cells under normal conditions.
cloxPIBN mice (Schmidt-Ullrich et al., 2001) were
crossed with CNP/Cre knock-in mice (Lappe-Siefke et al., 2003)
to obtain cloxPIBN;CNP/Cre mice (IBN mice) and
control mice (IBN mice), including cloxPIBN mice,
CNP/Cremice, and wild-type mice (Table 1, 2). IBNmice
appeared healthy and were indistinguishable from littermate
control mice. PCR analysis showed that the floxed STOP cassette
that prevents IBN translation was removed by Cre recombi-
nation in the CNS and PNS of IBNmice (Fig. 1A).Western
blot analysis showed that IBN was expressed in the CNS of
IBN mice (Fig. 1B). CC1, a marker for oligodendrocytes,
IHC showed that the number of oligodendrocytes in the CNS of
21-d-old IBN mice was comparable to IBN mice
(CC, p  0.9062; CE, p  0.4333; SC, p  0.7828; all t test; Fig.
1C,D,G). MBP IHC showed that IBN expression in oligo-
dendrocytes did not alter the degree ofmyelination in the CNS of
21-d-old IBN mice compared with IBN mice (Fig.
1E,F). Moreover, CC1 and MBP IHC showed that IBN ex-
pression in oligodendrocytes did not alter oligodendrocyte num-
bers or the degree of myelination in the CNS of adult mice (CC,
p 0.5363; CE, p 0.8105; SC, p 0.4502; all t test; Fig. 1H–L).
Therefore, these results demonstrate that NF-B is dispensable
for the viability and function of oligodendrocytes under normal
conditions.
Several in vitro studies suggest that NF-B activation is re-
quired for Schwann cell differentiation and myelin formation in
the PNS (Nickols et al., 2003; Limpert et al., 2013). Nevertheless,
a recent report showed that Schwann-cell-restricted deletion of
IKK2 has no effect onmyelin formation in the PNS in vivo (Mor-
ton et al., 2013). As described above, the floxed STOP cassette
Table 2. Summary of mouse crosses
Abbreviated name Genotype Cross
IBN cloxPIBN;CNP/Cremice cloxPIBNmice CNP/Cremice
IBN cloxPIBNmice or CNP/Cremice or wild type mice
IFN-;IBN GFAP/tTA;TRE/IFN-mice with Dox GFAP/tTA;CNP/Cremice TRE/IFN-;cloxPIBNmice
IFN-;IBN GFAP/tTA;TRE/IFN-mice without Doxa
IFN-;IBN GFAP/tTA;TRE/IFN-;cloxPIBN;CNP/Cremice with Dox
IFN-;IBN GFAP/tTA;TRE/IFN-;cloxPIBN;CNP/Cremice without Doxa
aMice were removed from Dox at E15 for developmental studies and on the first day of cuprizone treatment for cuprizone studies.
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that prevents IBN translation was also removed by Cre
recombination in the PNS of IBN mice. Interestingly, to-
luidine blue staining revealed normal myelination in the devel-
oping and adult PNS of IBN mice compared with
IBNmice (Fig. 2). These data provide additional evidence
that NF-B is not a major player in Schwann cell differentiation
and myelin formation in the PNS under normal conditions.
NF-B inactivation specifically in myelinating
oligodendrocytes exacerbates IFN--induced
hypomyelination in the developing CNS
Multiple pathological features ofMS lesions are recapitulated in the
developing CNS of mice that express IFN- ectopically in the CNS,
including oligodendrocyte death,myelin loss, T-cell infiltration,mi-
croglia/macrophage activation, and upregulation of inflammatory
mediators (Corbin et al., 1996;LaFerla et al., 2000;LinandLin, 2010;
Lin et al., 2014). Using the tetracycline-controllable system, we have
generatedGFAP/tTA;TRE/IFN-double-transgenicmice that allow
forcontrollable expressionof IFN- in theCNS(Linet al., 2004).We
showed that the expression of the transgene IFN- is repressed in
GFAP/tTA;TRE/IFN- double-transgenic mice treated with Dox
and that IFN- becomes detectable in the CNS of these mice after
	14 d of Dox removal (Lin et al., 2005, 2008). Our previous studies
showed that the presence of IFN- in the CNS of young, developing
mice stimulates inflammation, activates NF-B, and inducesmyeli-
nating oligodendrocyte death andmyelin loss (Lin et al., 2005, 2008;
Lin and Lin, 2010; Lin et al., 2012, 2014). Therefore, we determined
the effects ofNF-Bactivationonmyelinatingoligodendrocytes un-
der inflammatory conditions by using IFN--expressing mice.
GFAP/tTA mice were crossed with CNP/Cre mice to obtain
GFAP/tTA;CNP/Cre mice and TRE/IFN- mice were crossed
with cloxPIBN mice to obtain TRE/IFN-;cloxPIBN
mice. Then, GFAP/tTA;CNP/Cre mice were crossed with TRE/
IFN-;cloxPIBN mice to obtain GFAP/tTA;TRE/IFN-;
cloxPIBN;CNP/Crequadruplemice andGFAP/tTA;TRE/IFN-
double mice (Table 2). GFAP/tTA;TRE/IFN-;cloxPIBN;CNP/
Cre mice and GFAP/tTA;TRE/IFN- mice were treated with Dox
from conception to repress the transgenic IFN- expression. One
group of GFAP/tTA;TRE/IFN-; cloxPIBN;CNP/Cremice was
released from Dox at embryonic day 15 (E15) (IFN-;IBN
mice). Another group of GFAP/tTA;TRE/IFN-;cloxPIBN;
CNP/Cremicenever released fromDox served as controls (IFN-;
IBN mice). One group of GFAP/tTA;TRE/IFN- mice was
released fromDoxatE15 (IFN-;IBNmice).Another group
Figure 1. IBN expression does not affect themyelinating function of oligodendrocytes. A, PCR analysis using genomic DNA showing the floxed IBN allele (530 base pair) in the brain
(1), spinal cord (2), sciatic nerve (3), heart (4), lung (5), liver (6), and kidney (7) of IBNmice and IBNmice; however, IBN allele (130 bp, arrow) was only detected in the brain
(1), spinal cord (2), and sciatic nerve (3) of IBNmice. B, Western blot analysis showing that IBNmice expressed both IB and IBN (arrow) in the brain, whereas control
IBN-mice only expressed IB. C, D, G, CC1 IHC showing that oligodendrocyte-specific expression of IBN did not change oligodendrocyte numbers in the corpus callosum (CC),
cerebellum (CE), and spinal cord (SC) of 21-d-oldmice. E, F, MBP IHC showing that oligodendrocyte-specific expression of IBN did not affectmyelination in the CC of 21-d-oldmice.H, I, L, CC1
IHC showing that oligodendrocyte-specific expression of IBN did not change oligodendrocyte numbers in the CC, CE, and SC of 56-d-old mice. J, K, MBP IHC showing that oligodendrocyte-
specific expression of IBN did not affect myelination in the CC of 56-d-old mice. Scale bars, 50m. n 3 animals. Error bars indicate SD. n.s., Not significant.
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of GFAP/tTA;TRE/IFN- mice never released from Dox served as
controls (IFN-;IBN mice). We found that a number of
IFN-;IBNmice display tremor and ataxia as described in
ourprevious studies (Lin et al., 2005, 2008, 2014). Importantly, IFN-
;IBNmice exhibited a significantlymore severe tremoring
phenotype compared with IFN-;IBNmice (Table 3).
Double immunostaining for ASPA (a marker for oligoden-
drocytes) and the active form of p65 showed that immunoreac-
tivity for the active form of p65 was undetectable in the CNS of
the control IFN-;IBN mice and IFN-;IBN
mice (Fig. 3A–F,M). A number of cells, including ASPA-positive
oligodendrocytes, were positive for the active form of p65 in the
CNS of IFN-;IBNmice (p 0.0001, one-way ANOVA
with Tukey’s posttest; Fig. 3G– I,M). Although there were a few
cells positive for the active form of p65 in the CNS of IFN-;
IBN mice, none of the ASPA-positive oligodendrocytes
were positive for the active formof p65 in thesemice (Fig. 3J–M).
Although none of GFAP-positive astrocytes were positive for the
active form of p65 in the CNS of IFN-;IBN mice and
IFN-;IBN mice (Fig. 3N,O), the majority of CD11b-
positive microglia/macrophages were positive for the active
form of p65 in the CNS of these mice (Fig. 3P,Q). Therefore,
these results suggest that oligodendrocyte-specific expression of
IBN blocks NF-B activation selectively in oligodendrocytes
in the CNS of IFN--expressing mice.
As expected, we found that IBN expression alone had no
effect on oligodendrocytes ormyelin in the CNS of 18-d-oldmice
(CC1, p  0.4089; EM, p  0.8057, one-way ANOVA with
Tukey’s posttest) and that the presence of IFN- in theCNS alone
noticeably reduced oligodendrocyte numbers (p  0.021, one-
way ANOVA with Tukey’s posttest) and the degree of myelina-
tion in the CNS of 18-d-old mice (Fig. 4A–C,E–G,I–K,M,N).
Interestingly, CC1 IHC showed that the number of oligodendro-
cytes was further reduced in the CNS of IFN-;IBNmice
compared with IFN-;IBN mice (p  0.017, one-way
ANOVAwith Tukey’s posttest; Fig. 4C,D,M). MBP IHC showed
noticeably more severe myelin loss in the CNS of IFN-;
IBN mice compared with IFN-;IBN mice (Fig.
4G,H). Moreover, EM analysis showed that there were signifi-
cantly fewer myelinated axons in the CNS of IFN-;IBN
mice compared with IFN-;IBN mice (p  0.0001,
one-way ANOVA with Tukey’s posttest), which was further re-
duced in IFN-;IBN mice (p  0.0001, one-way
ANOVA with Tukey’s posttest; Fig. 4 I,K,L,N). Together, these
data suggest that oligodendrocyte-specific expression of IBN
blocks NF-B activation in oligodendrocytes and results in the
increased sensitivity of oligodendrocytes to the detrimental ef-
fects of IFN- during development.
NF-B is a master transcription factor that regulates the ex-
pression of genes involved in inflammation (Oeckinghaus et al.,
2011; Mc Guire et al., 2013; Herrington et al., 2016). We further
determined whether oligodendrocyte-specific expression of
IBN influences inflammation in the CNS of IFN--
expressing mice. CD11b IHC showed that the presence of IFN-
in the CNS alone strongly activated microglia/macrophages (Fig.
5A–C). Nevertheless, oligodendrocyte-specific expression of
IBNhadno significant effect on activation ofmicroglia/mac-
rophages in the CNS of IFN--expressing mice (Fig. 5C,D). CD3
IHC also revealed comparable T-cell infiltration in the CNS of
IFN-;IBNmice and IFN-;IBNmice (Fig. 5E–
H). Real-time PCR analysis showed comparable levels of IFN-
in the CNS of IFN-;IBN mice and IFN-;IBN
mice (IFN-;IBNmice vs IFN-;IBNmice, p
0.0001; IFN-;IBNmice vs IFN-;IBNmice, p
0.8957; one-way ANOVA with Tukey’s posttest; Fig. 5I). More-
over, the presence of IFN- in the CNS alone strongly stimulated
the expression of tumor necrosis factor  (TNF, IFN-;
IBN mice vs IFN-;IBN mice, p  0.0008; one-
way ANOVA with Tukey’s posttest) and inducible nitric oxide
synthase (iNOS, IFN-;IBNmice vs IFN-;IBN
mice, p 0.0104; one-way ANOVAwith Tukey’s posttest); how-
ever, oligodendrocyte-specific expression of IBN did not
affect the expression of TNF or iNOS significantly in the CNS of
IFN--expressingmice (TNF: IFN-;IBNmice vs IFN-
;IBNmice, p 0.9952; iNOS: IFN-;IBNmice
vs IFN-;IBN mice, p  0.9987; one-way ANOVA with
Tukey’s posttest; Fig. 5I). These results suggest that NF-B inac-
tivation specifically in oligodendrocytes has no effect on inflam-
mation in the CNS of IFN--expressing mice. Collectively, our
data indicate that NF-B activation in myelinating oligodendro-
cytes cell autonomously protects the cells against inflammation
in the developing CNS of IFN--expressing mice.
NF-B inactivation does not affect the viability or function of
oligodendrocytes in the cuprizone model
The cuprizonemodel is regarded as one of the bestmousemodels
to understand the processes of remyelination in the CNS and is
increasingly used to study the mechanisms of remyelination in
MS (Matsushima and Morell, 2001; Denic et al., 2011). It is be-
lieved that cuprizone acts directly on mature oligodendrocytes,
resulting in mature oligodendrocyte apoptosis and subsequent
demyelination in the corpus callosum. Oligodendrocytes pro-
genitor cells proliferate and differentiate within the lesion and
oligodendrocytes then repopulate the area, resulting in complete
remyelination after several weeks of cuprizone removal. A previ-
ous study showed that CNS-restricted deletion of IKK2 prevents
mature oligodendrocyte apoptosis and demyelination in the cu-
prizone model; however, oligodendrocyte-restricted deletion of
IKK2 had no effect on the demyelination and remyelination pro-
cesses in this model (Raasch et al., 2011). Herein, we investigated
the effects of oligodendrocyte-specific expression of IBN on
Figure 2. IBN expression did not affect the myelinating function of Schwann cells.
A, B, Toluidine blue staining showing normal myelination in the sciatic nerve of 21-d-old
IBNmice compared with IBNmice. C, D, Toluidine blue staining showing nor-
mal myelination in the sciatic nerve of 56-d-old IBNmice compared with IBN
mice. Scale bars, 10m. n 4 animals.
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oligodendrocyte apoptosis and regeneration in the cuprizone
model.
Six-week-old male cloxPIBN;CNP/Cre mice (IBN
mice) and control mice (IBNmice), including cloxPIBN
mice, CNP/Cre mice, and wild-type mice, were treated with 0.2%
cuprizone chow for up to 6 weeks. In accordance with previous
reports (MatsushimaandMorell, 2001;Denic et al., 2011), therewas
severe oligodendrocyte loss and demyelination in the corpus callo-
sum of IBNmice after 5 weeks of cuprizone treatment com-
pared with untreated mice (Fig. 6A,C,E,F,H,J). We found that
oligodendrocyte-specific expressionof IBNdidnot affect oligo-
dendrocyte loss or demyelination in the corpus callosum after 5
weeks of cuprizone treatment (p 0.8814, t test; Fig. 6A–J). These
results suggest the minimal role of NF-B in oligodendrocytes dur-
ing the cuprizone-induced demyelination process.
To determine the effects ofNF-Bon remyelinating oligoden-
drocytes, 6-week-old male IBN and IBN mice were
treated with 0.2% cuprizone chow for 6 weeks and then returned
to a normal diet for 3 weeks to allow remyelination to occur. CC1
immunostaining showed that the number of remyelinating oli-
godendrocytes was comparable in the corpus callosum of
IBN mice and IBN mice 3 weeks after cuprizone
removal (p  0.1046, t test; Fig. 6K,L,O). Moreover, MBP im-
munostaining showed that oligodendrocyte-specific expression
Table 3. IFN-;IBNmice displayed amore severe tremor than IFN-;IBNmice
Mouse line No tremor (%) Mild tremor (%) Tremor (%) Severe tremor (%)
IFN-;IBN (n 40) 100 0 0 0
IFN-;IBN (n 36) 100 0 0 0
IFN-;IBN (n 41) 66 12 15 7
IFN-;IBN (n 20) 5* ( p 0.0001) 5 ( p 0.5127) 35* ( p 0.0228) 55* ( p 0.0001)
Mild tremor indicates tremor only in tail; tremor is tremor in tail and body; severe tremor is whole-body tremor and occasional seizures.
*p 0.05.
Figure 3. Oligodendrocyte-specific expression of IBN inhibited IFN--induced NF-B activation selectively in oligodendrocytes. A–F, ASPA and active p65 double immunostaining
showing that active p65 was undetectable in oligodendrocytes in the CNS of 18-d-old IFN-; IBNmice and IFN-; IBNmice. G–I, Active p65 became detectable in a number
of oligodendrocytes (arrow and arrowheads) of IFN-; IBNmice. Inset, ASPA and active p65 double-positive cell (arrow). J–L, None of ASPA-positive cells were positive for active p65 in
IFN-;IBNmice.M, Quantitative analysis of oligodendrocytes positive for the active form of p65 in the CNS. N, O, None of GFAP-positive astrocytes were positive for active p65 in either
IFN-;IBNmice or IFN-;IBNmice. P,Q, Themajority of CD11b-positivemicroglia/macrophages were positive for active p65 in both IFN-;IBNmice and IFN-;
IBNmice. Scale bars, 20m. n 4 animals. Error bars indicate SD. *p 0.05.
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of IBN did not change the degree of remyelination in the
demyelinated lesions significantly 3 weeks after cuprizone re-
moval (Fig. 6M,N). Therefore, these data suggest the minimal
role of NF-B in remyelinating oligodendrocytes in demyeli-
nated lesions in adult mice.
NF-B inactivation in remyelinating oligodendrocytes
aggravates IFN--induced remyelination failure in the
cuprizone model
Our previous studies show that the presence of IFN- in the CNS
suppresses oligodendrocyte regeneration and remyelination in
the cuprizone-induced demyelinated lesions (Lin et al., 2006,
2014). Therefore, we used the cuprizone model to assess the ef-
fects of NF-B activation on remyelinating oligodendrocytes in
response to IFN-. Six-week-old male GFAP/tTA;TRE/IFN-;
cloxPIBN;CNP/Cre quadruple mice and GFAP/tTA;TRE/
IFN- double mice that had been maintained on Dox from
conception were treated with 0.2% cuprizone chow for 6 weeks
and then returned to a normal diet for 3 weeks. One group of
GFAP/tTA;TRE/IFN-;cloxPIBN;CNP/Cre mice were re-
leased fromDox starting on the day of cuprizone treatment (IFN-
;IBN mice). Another group of GFAP/tTA;TRE/IFN-;
cloxPIBN;CNP/Cre mice were never released from Dox to
serve as controls (IFN-;IBNmice).One group ofGFAP/
tTA;TRE/IFN-mice were released fromDox starting on the day
of cuprizone treatment (IFN-;IBN mice). Another
group of GFAP/tTA;TRE/IFN- mice were never released from
Dox to serve as controls (IFN-;IBNmice).
We found that oligodendrocyte-specific expression of
IBN did not change the number of remyelinating oligoden-
drocytes or the degree of remyelination significantly in the corpus
callosum of the control animals 3 weeks after cuprizone removal
(CC1, p  0.9552; EM, p 
 0.9999; one-way ANOVA with
Tukey’s posttest; Fig. 7A,B,E,F, I, J,M,N). Consistent with our
previous studies (Lin et al., 2006, 2014), we found that the pres-
ence of IFN- in theCNS impaired oligodendrocyte regeneration
significantly (p  0.0037, one-way ANOVA with Tukey’s post-
Figure 4. Oligodendrocyte-specific expression of IBN exacerbated IFN--induced hypomyelination during development. A–D,M, CC1 IHC showing comparable oligodendrocyte numbers
in the corpus callosum of 18-d-old IFN-;IBNmice and IFN-;IBNmice. Oligodendrocyte numbers were significantly reduced in IFN-;IBNmice and were further
reduced in IFN-;IBNmice.E–H,MBP IHC showing a comparable degree ofmyelination in the corpus callosumof 18-d-old IFN-;IBNmice and IFN-;IBNmice. The
degree of myelination was noticeably reduced in IFN-;IBN mice and was further reduced in IFN-;IBN mice. I–L, N, EM analysis showing a comparable percentage of
myelinated axons in the corpus callosum of 18-d-old IFN-;IBN mice and IFN-;IBN mice. The percentage of myelinated axons was significantly reduced in IFN-;
IBNmice and further reduced in IFN-;IBNmice. Scale bars: A–H, 50m; I–L, 1m. n 4 animals. Error bars indicate SD. *p 0.05. n.s., Not significant.
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test) and remyelination in the corpus callosum of IFN-;
IBN mice compared with control IFN-;IBN mice
and IFN-;IBN mice (Fig. 7A–C,E–G,I–K,M,N).
Importantly, the number of remyelinating oligodendrocytes in the
corpus callosum of IFN-;IBN mice was further reduced
compared with IFN-;IBN mice (p  0.0104, one-way
ANOVAwith Tukey’s posttest; Fig. 7C,D,M). MBP immunostain-
ing also showed noticeably weaker MBP immunoreactivity in
the corpus callosum of IFN-;IBN mice than IFN-;
IBNmice (Fig. 7G,H).Moreover, EManalysis confirmed that
there were fewer remyelinated axons in the corpus callosumof IFN-
;IBNmice compared with IFN-;IBNmice (p
0.0001, one-way ANOVA with Tukey’s posttest) and IFN-;
IBNmice (p 0.0001, one-way ANOVAwith Tukey’s post-
test), which was further reduced in IFN-;IBN mice (p
0.0001, one-way ANOVAwith Tukey’s posttest; Fig. 7I–L,N). Col-
lectively, these data demonstrate that NF-B inactivation in remy-
elinating oligodendrocytes increases the sensitivity of the cells to the
detrimental effects of IFN- in the cuprizonemodel.
NF-B inactivation in mature oligodendrocytes increases the
susceptibility of mice to EAE
EAE, the primary animal model used in MS research, displays
many of the clinical, pathological, and immunological features of
MS (Kipp et al., 2017; Lassmann and Bradl, 2017). Our previous
study demonstrated NF-B activation in oligodendrocytes in the
MOG-EAE model (Lin et al., 2013). We examined the effects of
NF-B inactivation in mature oligodendrocytes on the develop-
ment of MOG-EAE. Eight-week-old female cloxPIBN;CNP/
Cremice (IBNmice) and control mice (IBNmice),
including cloxPIBN mice, CNP/Cre mice, and wild-type
mice, were immunized with MOG35-55 peptide to induce EAE.
IBN mice developed a typical EAE disease course (Fig.
8A,B). Interestingly, IBNmice developed very severe EAE:
22 of 27 mice died by PID 21 (p 0.0367 to0.0001, two-way
ANOVA of disease course with a Sidak’s multiple-comparisons
test, Fig. 8A; p  0.0001, t test for peak score, Fig. 8B). The
majority of these mice died suddenly at	PID 14 (ranging from
PID 10–21) before they exhibited classical EAE clinical symp-
toms such as flaccid tail, hindlimb paresis, or hindlimb paralysis.
Surviving IBNmice (5 of 27) displayed EAE clinical symp-
toms similar to IBNmice (Fig. 8B). Because of early, sud-
den death without obvious clinical symptoms, we were not able
to collect CNS tissues to performhistopathologic analyses despite
the large number of IBNmice (n 27 animals) used in this
experiment.
EAE is initiated by T-cell priming in the mouse peripheral
immune system and subsequent autoimmune reactions against
oligodendrocytes and myelin in the CNS (Kipp et al., 2017; Lass-
mann and Bradl, 2017). We investigated whether T-cell priming
was altered in IBN mice during EAE. Spleen leukocytes
were generated from IBNmice and IBNmice under-
going EAE at PID 10 and their in vitro response to a secondary
exposure to MOG35–55 peptide was analyzed. Interestingly, in
vitro recall assays showed that the abilities of T cells generated
from IBN mice to proliferate (p  0.0996–0.8696, two-
way ANOVA of disease course with a Sidak’s multiple-
comparisons test) and to produce the cytokines IFN- (p 
Figure5. Oligodendrocyte-specific expression of IBNdidnot alter inflammation in the CNSof IFN--expressingmice.A–D, CD11b IHC showing strong activation ofmicroglia/macrophages
in the corpus callosum of 18-d-old IFN-;IBNmice compared with IFN-;IBNmice and IFN-;IBNmice. However, the degree of microglia/macrophage activation
was comparable in IFN-;IBNmice and IFN-;IBNmice. E–H, CD3 IHC showing few infiltrating T cells (arrow) in the corpus callosum of 18-d-old IFN-;IBNmice
compared with IFN-;IBNmice and IFN-;IBNmice. However, the numbers of infiltrating T cells (arrow) in IFN-;IBNmice were comparable to those in IFN-;
IBN mice. I, Real-time PCR analysis revealed dramatically increased the levels of IFN-, TNF-, and iNOS in the brains of 18-d-old IFN-;IBN mice compared with IFN-;
IBNmice and IFN-;IBNmice. However, the levels of IFN-, TNF-, and iNOSwere comparable in IFN-;IBNmice and IFN-;IBNmice. Scale bars, 50m.
n 4 animals. Error bars indicate SD. *p 0.05. n.s., Not significant.
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0.3408, t test), IL-4 (p  0.1058, t test),
and IL-17A (P  0.0949, t test) were
not changed significantly compared with
those from IBN mice (Fig. 8C–F).
A large number of studies demonstrate
that impairedNF-B activation in inflam-
matory cells suppresses inflammation
(Yan and Greer, 2008; Mc Guire et al.,
2013; Hao et al., 2016). Therefore, it is un-
likely that the exacerbated EAE displayed
by IBNmice is due to enhanced in-
flammation even if there is a leaky expres-
sion of IBN in inflammatory cells in
these mice. Conversely, our studies de-
scribed above showed the detrimental
effects of NF-B inactivation on oligo-
dendrocytes in response to inflammation.
Several studies have shown that increased
vulnerability of mature oligodendrocytes
to inflammation results in increased EAE
disease severity (Hisahara et al., 2001;
Hussien et al., 2014, 2015). Collectively,
these data raise the possibility that NF-B
inactivation in mature oligodendrocytes
exacerbates EAE disease severity by ren-
dering oligodendrocytes vulnerable to
inflammation.
Discussion
The transcription factor NF-B plays a
critical role in inflammatory diseases by
regulating inflammation and cell viability
(Oeckinghaus et al., 2011; Mc Guire et al.,
2013; Herrington et al., 2016). NF-B can
be activated by diverse stimuli, including
various inflammatory mediators, growth
factors, and cellular stresses, through
a variety of ways, including the IKK2-
dependent canonical pathway, the nonca-
nonical pathway, and atypical pathways
(Hayden and Ghosh, 2012; Mincheva-
Tasheva and Soler, 2013).MS andEAE are
full-blown inflammatory diseases in the
CNS (Frohman et al., 2006; Lassmann and
Bradl, 2017). NF-B is activated in the
CNS cells in these diseases through both
the IKK2-dependent pathway and IKK2-
independent pathways. It is well docu-
mented that NF-B is one of master
regulators of inflammation inMS and EAE (Yan andGreer, 2008;
McGuire et al., 2013;Hao et al., 2016). Correlative in vitro studies
point to the cytoprotective effects of NF-B activation on oligo-
dendrocytes in these diseases (Nicholas et al., 2001; Hamanoue et
al., 2004; Lin et al., 2012). However, to date, attempts to under-
stand the role of NF-B activation in oligodendrocytes inMS and
EAE have been unsuccessful.
Oligodendrocyte regeneration and subsequent remyelina-
tion is essential and necessary to restore neurological function
in MS patients; however, remyelination is insufficient in MS
lesions (Franklin and ffrench-Constant, 2008; Kotter et al.,
2011). (Re)myelinating oligodendrocytes must produce enor-
mous amounts of membrane proteins and lipids to assemble
myelin sheaths. Due to an extremely high rate of metabolism,
(re)myelinating oligodendrocytes are highly vulnerable to in-
flammation (Lin and Popko, 2009; Bradl and Lassmann,
2010). Death of (re)myelinating oligodendrocytes induced by
inflammation contributes to remyelination failure in MS
(Bradl and Lassmann, 2010; Watzlawik et al., 2010; Stone and
Lin, 2015). Therefore, it is important to understand the role of
NF-B activation in (re)myelinating oligodendrocytes in MS
lesions. In this study, we generated a mouse model that expresses
IBN, a super-suppressor of NF-B, specifically in oligodendro-
cytes and demonstrated that oligodendrocyte-specific expression of
IBN had no effect on (re)myelinating oligodendrocytes in the
developing CNS and in cuprizone-induced demyelinated lesions.
IFN- is regarded as amajor contributing factor to poor remyelina-
tion in MS lesions (Lin et al., 2006, 2014; Stone and Lin, 2015).
Figure 6. Oligodendrocyte-specific expression of IBN did not influence demyelination or remyelination in the cuprizone
model. A, B, E, CC1 immunostaining showing comparable oligodendrocyte numbers in the corpus callosum of 6-week-old
IBN mice and IBN mice. C, D, MBP immunostaining showing comparable, strong myelination in the corpus
callosum of 6-week-old IBNmice and IBNmice. F, G, J, CC1 immunostaining showing comparable oligodendro-
cytes loss in the corpus callosum of IBN mice and IBN mice after 5 weeks of cuprizone treatment. H, I, MBP
immunostaining showing comparable demyelination in the corpus callosum of IBN mice and IBN mice after 5
weeks of cuprizone treatment. K, L, O, CC1 immunostaining showing comparable oligodendrocyte regeneration in the corpus
callosum of IBN mice and IBN mice 3 weeks after cuprizone removal. M, N, MBP immunostaining showing
comparable remyelination in the corpus callosumof IBNmiceand IBNmice3weeksafter cuprizone removal. Scale
bars, 50m. n 4 animals. Error bars indicate SD. n.s., Not significant.
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Evidence suggests that IFN- exerts its detrimental effects on
(re)myelinating oligodendrocytes by stimulating inflamma-
tion and by acting directly on the cells (Popko and Baerwald,
1999; Lin et al., 2006, 2008; Lin and Lin, 2010; Lin et al., 2014).
Interestingly, we showed here that oligodendrocyte-specific
expression of IBN blocked NF-B activation selectively in
oligodendrocytes and exacerbated myelinating oligodendro-
cyte death and hypomyelination, but did not alter inflamma-
tion in the developing CNS of IFN--expressing mice.
Moreover, we found that NF-B inactivation specifically in
oligodendrocytes aggravated IFN--induced remyelinating
oligodendrocyte death and remyelination failure in the cupri-
zone model. Collectively, these results suggest that NF-B
activation protects (re)myelinating oligodendrocytes cell au-
tonomously against inflammation in MS lesions.
MS and EAE are thought to be initiated by an autoimmune
reaction against oligodendrocytes and myelin (Frohman et al.,
2006; Bradl and Lassmann, 2010). Several studies have shown
that mature oligodendrocyte apoptosis is the earliest structural
change in newly forming demyelinating lesions in MS and EAE
(Barnett and Prineas, 2004; Lin et al., 2013). A number of studies
have shown thatmature oligodendrocytes with an enhanced abil-
ity to resist inflammation make mice resistant to EAE (Hisahara
et al., 2000; Mc Guire et al., 2010; Lin et al., 2013). In contrast,
mature oligodendrocytes with a compromised ability to respond
to inflammation render mice susceptible to EAE (Hisahara et al.,
2001;Hussien et al., 2014, 2015).We showed here that IBN
mice developed extremely severe EAE with very high mortality.
Unfortunately, we were not able to collect tissues to assess tissue
damage or inflammation in the CNS of these mice due to early,
sudden death without noticeable clinical phenotypes. Although a
number of studies demonstrate that CNP/Cre knock-in mice ex-
press Cre specifically in oligodendrocytes and Schwann cells
(Lappe-Siefke et al., 2003; Hussien et al., 2014, 2015), the possi-
bility of a leaky expression of IBN in inflammatory cells in
IBNmice cannot be ruled out completely.Nevertheless, we
Figure 7. Oligodendrocyte-specific expression of IBN exacerbated IFN--induced remyelination failure in the cuprizone model. A–D, M, CC1 immunostaining showing comparable
oligodendrocyte numbers in the corpus callosumof IFN-;IBNmice and IFN-;IBNmice 3weeks after cuprizone removal. Oligodendrocyte numberswere significantly reduced
in IFN-;IBN mice and were further reduced in IFN-;IBN mice. E–H. MBP immunostaining showing a comparable degree of remyelination in the corpus callosum of
IFN-;IBN mice and IFN-;IBN mice 3 weeks after cuprizone removal. The degree of remyelination was noticeably reduced in IFN-;IBN mice and was further
reduced in IFN-;IBNmice. I–L,N, EManalysis showinga comparablepercentageofmyelinatedaxons in the corpus callosumof IFN-;IBNmiceand IFN-;IBNmice
3 weeks after cuprizone removal. The percentage of myelinated axons was significantly reduced in IFN-;IBNmice and further reduced in IFN-;IBNmice. Scale bars: A–H,
50m; I–L, 1m. n 4 animals. Error bars indicate SD. *p 0.05. n.s., Not significant.
Stone et al. • NF-B Activation Protects against Inflammation J. Neurosci., September 20, 2017 • 37(38):9332–9344 • 9341
showed that T-cell priming was not altered in IBN mice
undergoing EAE. Importantly, it is well documented that NF-B
activation in inflammatory cells increases EAE disease severity
(Yan and Greer, 2008; McGuire et al., 2013; Hao et al., 2016).
Therefore, the possibility that the exacerbated EAE displayed by
IBN mice is caused by enhanced inflammation due to an
undesired leaky expression of IBN in inflammatory cells is
very remote. Rather, our data suggest that NF-B activation in
mature oligodendrocytes is protective, protecting mice against
EAE.
Although NF-B is increasingly recognized as a prosurvival
transcription factor, the precise molecular mechanisms respon-
sible for the cytoprotective effects of NF-B remain elusive.
Several studies have shown that NF-B activation exerts cytopro-
tection through the induction of anti-apoptotic genes including
cIAPs, cFLIP, Bcl-2, Bcl-xL, TRAF1, and TRAF2 (Karin and Lin,
2002; Oeckinghaus et al., 2011; Mincheva-Tasheva and Soler,
2013). It is possible that the cytoprotective effects of NF-B on
oligodendrocytes under inflammatory conditions results from
the combined upregulation of multiple of these anti-apoptotic
genes. Conversely, a recent study showed that upregulation of
cFLIP protects cultured primary oligodendrocytes against the cy-
totoxicity of TNF- and that downregulation of cFLIP makes
oligodendrocytes sensitive to inflammation in the CNS of trans-
genic mice that ectopically express human IL-1 in astrocytes
(Tanner et al., 2015). An alternative, but not mutually exclusive,
possibility is that NF-B activation protects oligodendrocytes
against inflammation through induction of cFLIP. Unfortu-
nately, the mouse models used in this study do not allow us to
assess the contribution of cFLIP to the cytoprotective effects of
NF-B activation on oligodendrocytes. A mouse model that al-
lows for controllable activation of NF-B and inactivation of
cFLIP specifically in oligodendrocytes would be an ideal model
with which to address this important question.
Data indicate that NF-B is activated in oligodendrocytes in
MS and EAE through both the IKK2-dependent pathway and
IKK2-independent pathways (Yan and Greer, 2008; Mc Guire et
al., 2013). For example, our recent study shows that activation of
pancreatic endoplasmic reticulum kinase (PERK) in response to
endoplasmic reticulum stress suppresses IB translation by
phosphorylating translation initiation factor 2 (eIF2), result-
ing in NF-B activation in oligodendrocytes in the CNS of EAE
mice (Lin et al., 2013). Moreover, the presence of IFN- in the
CNS can activate NF-B in oligodendrocytes through both the
IKK2-dependent pathway and IKK2-independent pathways. For
example, our previous study demonstrates that IFN- can acti-
vate NF-B in oligodendrocytes by suppressing of IB transla-
tion through the PERK-eIF2 pathway (Lin et al., 2012). We
showed here that IBN expression eliminated NF-B activa-
tion in oligodendrocytes in the CNS of IFN--expressing mice,
Figure 8. Oligodendrocyte-specific expression of IBN increased EAE disease severity. A, IBN mice develop much more severe EAE compared with IBN mice. Error bars
indicate SEM. IBNmice, n 12 animal; IBNmice, n 27 animal. *p 0.05. B, Peak clinical score for individual mice. IBNmice, n 12 animal; IBNmice, n
27 animal. *p 0.05. C, BrdU cell proliferation assay showing that oligodendrocyte-specific expression of IBN did not affect T-cell proliferation in response to MOG35–55 peptide. n 4
animals. Error bars indicate SD. n.s., Not significant.D–F, ELISA analysis showing that oligodendrocyte-specific expression of IBN did not affect significantly the ability of T cells to produce the
cytokines IFN-, IL-17A, or IL-4 in response to MOG35–55 peptide. n 4 animals. Error bars indicate SD. n.s., Not significant.
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suggesting that NF-B activation in oligodendrocytes under in-
flammatory conditions via both the IKK2-dependent pathway
and IKK2-independent pathways can be blocked effectively by
expression of IBN. In contrast, a previous study shows that
oligodendrocyte-specific deletion of IKK2 using IKK2FL;MOG/
Cre mice does not affect the development of EAE (Raasch et al.,
2011). The minimal effects of oligodendrocyte-specific deletion
of IKK2 in EAE likely reflect the inability of IKK2 deletion alone
to impair NF-B activation in the cells under inflammatory
conditions.
In summary, using a mouse model that expresses IBN, a
super-suppressor of NF-B, specifically in oligodendrocytes in
the CNS, the results presented in this study demonstrate the dis-
pensable role of NF-B in oligodendrocytes under physiological
conditions and the cytoprotective role of NF-B activation in
oligodendrocytes in animal models of MS. These findings impli-
cate that NF-B activation protects oligodendrocytes (both ma-
ture and remyelinating oligodendrocytes) against inflammation
in MS patients, suggesting a therapeutic cytoprotective potential of
NF-B activation in MS. In contrast, a number of studies have
shown that NF-B activation in T cells, microglia/macrophages, or
astrocytes enhances inflammation and facilitates the pathogenesis of
MS and EAE, implying the therapeutic anti-inflammatory potential
of NF-B inhibition in MS (Brambilla et al., 2009; Mc Guire et al.,
2013; Yin et al., 2013; Hao et al., 2016). Therefore, it is unlikely that
NF-B is an ideal therapeutic target for MS due to its paradoxical
effects in this disease.
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